Ranbaxy Whistleblower’s New Mission: How to Detect Fraud from Afar
This article was originally published in The Gold Sheet
Executive Summary
A decade ago, Dinesh Thakur was able to perceive data integrity issues at Ranbaxy because of his unique position in the company. Today, he’s working to help pharmaceutical companies monitor their global manufacturing networks to detect such issues wherever they might occur.
You may also be interested in...
US FDA: Sun’s Mohali Plant Dropped Ball On Worker’s Data Integrity Allegations
Was backdating of GMP records part of an effort to move suspect product? FDA investigators found Sun was leaving lots of stones unturned in its effort to find out.
The Quality Lowdown: Stability Testing, OOS Findings, Major Quality Failures Cited
Cadila (now Zydus), Wuxi, Accu-Biochem, Agropharma, Dr Retter stung by US FDA inspections that focused on failings in a range of core quality areas.
The Mind-Numbing Way FDA Uncovers Data Integrity Lapses
An FDA official encourages industry to use this method to audit supply chains for data integrity – even though it can be mind-numbingly tedious.